Core Viewpoint - Biorestorative Therapies, Inc. reported a quarterly loss of 0.56, indicating a positive earnings surprise of 10.71% [1] Financial Performance - The company posted revenues of 0.07 million in the same quarter last year [2] - Over the last four quarters, Biorestorative Therapies has surpassed consensus EPS estimates three times and has topped consensus revenue estimates three times as well [2] Stock Performance - Biorestorative Therapies shares have declined approximately 17.8% since the beginning of the year, contrasting with the S&P 500's gain of 12.1% [3] - The current Zacks Rank for the stock is 3 (Hold), indicating that shares are expected to perform in line with the market in the near future [6] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is -0.03 million, and for the current fiscal year, it is -0.13 million [7] - The estimate revisions trend for Biorestorative Therapies is mixed, and future earnings expectations will depend on management's commentary during the earnings call [4][6] Industry Context - The Medical - Biomedical and Genetics industry, to which Biorestorative Therapies belongs, is currently ranked in the top 29% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8]
Biorestorative Therapies, Inc. (BRTX) Reports Q2 Loss, Tops Revenue Estimates